Io­n­is touts PhII MASH study da­ta that fea­ture its DGAT2 an­ti­sense in­hibitor

Io­n­is said on Wednes­day that its meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH) drug hit the pri­ma­ry and sec­ondary end­points of a Phase II tri­al, no­tably show­ing his­to­log­ic im­prove­ment and MASH res­o­lu­tion.

The drug, a DGAT2 an­ti­sense in­hibitor dubbed ION224, was test­ed at 120 mg and 90 mg in 160 pa­tients across 49 weeks. Io­n­is used the NAFLD Ac­tiv­i­ty Score to mea­sure liv­er his­to­log­ic im­prove­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER